Prosztatarák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · P01

  Understanding and targeting treatment-associated lineage plasticity in cancer

  Columbia University Health Sciences· New York, Egyesült Államok· 2 729 322 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  The role of GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer and immune evasion

  Methodist Hospital Research Institute· Houston, Egyesült Államok· 514 864 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Elucidating upstream and downstream NUAK2 mechanisms in neuroendocrine prostate cancer

  Augusta University· Augusta, Egyesült Államok· 518 589 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R56

  The role of AKT isoform-preferred substrates in prostate cancer aggressiveness

  Roswell Park Cancer Institute Corp· Buffalo, Egyesült Államok· 130 125 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R01

  Analysis of epithelial heterogeneity and plasticity in prostate development and cancer

  Columbia University Health Sciences· New York, Egyesült Államok· 613 866 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 202 125 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Törökország· EU contribution 398 612 EUR· until 2029. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. szept.

10 of 74 running projects, newest first. Listed amounts together: 30,6 M USD + 116,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Deciphera Pharmaceuticals, LLC· Frissítve: 2026. márc. 5.

  “Trial terminated due to a business decision, not based on any safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Cancer morbidity and mortality in individuals with obsessive-compulsive disorder: a population-based and sibling cohort study in Sweden and Denmark.

  BMC Med, 2026. nov.

• Comparative functional and oncologic outcomes of radical prostatectomy using the da Vinci Xi versus da Vinci 5: an inverse probability-weighted analysis.

  World J Urol, 2026. nov.

• Sleep duration and prostate cancer-specific mortality in the Southern Community Cohort Study.

  Cancer Causes Control, 2026. okt.

• Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care.

  Support Care Cancer, 2026. okt.

• Pathological fracture as initial manifestation of malignancy and survival based on diagnoses: a register-based cohort study from the Swedish Fracture Register and the Swedish Cancer Register.

  Acta Orthop, 2026. okt.

• Oncological outcomes after Senhance robot-assisted radical prostatectomy: biochemical recurrence and risk stratification in a large single-centre cohort.

  J Robot Surg, 2026. okt.

• Association of Travel Time With Definitive Prostate Cancer Treatment: A United States Registry Cohort Study.

  Cancer Med, 2026. okt.

• Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer.

  JAMA Netw Open, 2026. okt.

• Leveraging Artificial Intelligence to Monitor Patients With Prostate Cancer in a Retrospective Cohort of Radiation Oncology Clinic Patients.

  Clin J Oncol Nurs, 2026. szept.

• TAPESTRY study: impact of prior transurethral resection of the prostate on outcomes after robot-assisted radical prostatectomy: a propensity score-matched cohort study.

  J Robot Surg, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.